Telmisartan^▼ licence change
Since these NPCi materials were published, telmisartan^▼ has been licensed for cardiovascular prevention (see Summary of Product Characteristics for details). To accompany this licence change, telmisartan^▼ has become a black triangle drug intensively monitored by the MHRA and CHM. This licence extension does not change any of the messages in these materials.

We have produced data-focussed commentaries to highlight areas where there appear to be differences between the evidence-base, as described elsewhere on this floor, and current clinical practice. These resources can be read on the screen by clicking the 'flash' version, or by downloading and printing the 'PDF' version.

This commentary covers the prescribing of ACE inhibitors and angiotensin-2 receptor antagonists (A2RA) across England and highlights some key issues around the evidence for these agents.

Date updated - February 2010